Merck gets nod from US panel on sleeping pill, but safety flagged
This article was originally published in Scrip
Executive Summary
After a day of addressing concerns about suicide, night terrors and drowsy, dangerous drivers, Merck & Co. convinced a panel of US FDA advisers that its experimental sleeping pill suvorexant was effective and safe at low doses.